Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIB Gastric Cancer: early-phase trial registry
1 of 4 indexed Stage IIIB Gastric Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Stage IIIB Gastric Cancer: 4 US clinical trials tracked, 1 recruiting.
Stage IIIB Gastric Cancer is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition stage-iiib-gastric-cancer
OPEN 1 | RECR 25% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Stage IIIB Gastric Cancer lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIB Gastric Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIB Gastric Cancer is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
NCT02366819
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
NCT00982592
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
NCT01178944
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
NCT01612546
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIB Gastric Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIB Gastric Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIB Gastric Cancer page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage IIIB Gastric Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Roswell Park Cancer Institute sponsors the most Stage IIIB Gastric Cancer trials on record, review their full trial history before evaluating a specific study. See Roswell Park Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIB Gastric Cancer condition card totals 4 registered trials; most-linked intervention Oxaliplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.